RAS mutations predict recurrence-free, overall survival in colorectal liver metastases

SAN DIEGO — When compared to wild-type RAS, mutant RAS colorectal liver metastases recurred earlier and had worse overall survival after repeat hepatectomy, pointing toward the importance of knowing RAS mutation status, according to data presented at DDW 2016.

“Preoperative determination of RAS mutation status prior to repeat hepatectomy for recurrent colorectal liver metastases may help guide treatment decisions,” Jason Denbo, MD, from MD Anderson, said during his presentation.

Denbo presented data on patients who underwent repeat hepatectomies from 2005 to 2014 (n = 98) who had known RAS mutation status, of which they determined 64 had wild-type RAS and 34 had mutant RAS.

Mutant RAS had worse recurrence-free survival at 6.1 months vs. 12.2 months in wild-type RAS (P = .028) and mutant RAS had worse overall survival at 26.6 months vs. 42.5 months in wild-type RAS (P = .005).

Denbo said they looked at sex, number of tumors and major resection along with mutation status, but mutant RAS was the only strong predictor for recurrence-free survival (HR = 1.71; 95% CI, 1.04-2.78; P = .04) and for overall survival (HR = 2.1, 95% CI, 1.11-3.98; P = .02).

“RAS mutation status is a predictor of recurrence-free survival and overall survival in patients who undergo repeat hepatectomy for recurrent colorectal liver metastases,” Denbo said. – by Katrina Altersitz

Reference:

Denbo J, et al. Abstract #219. Presented at: Digestive Disease Week; May 21-24, 2016; San Diego.

Disclosures: Denbo reports no relevant financial disclosures.